No Loading Dose Required When Switching from Plavix to Eliquis
When transitioning from clopidogrel (Plavix) to apixaban (Eliquis) in a patient with chronic atrial fibrillation, simply discontinue Plavix and start Eliquis at the standard maintenance dose—no loading dose is necessary. 1
Switching Protocol
The FDA-approved prescribing information for Eliquis provides clear guidance for this exact scenario:
- Discontinue Plavix completely
- Start Eliquis at the usual time of the next scheduled Plavix dose 1
- No bridging anticoagulation is required
- No loading dose is indicated
This straightforward approach differs from switching between anticoagulants (like warfarin to Eliquis), where INR monitoring is needed. Since Plavix is an antiplatelet agent rather than an anticoagulant, the transition is simpler.
Determining the Correct Eliquis Dose
The appropriate starting dose depends on specific patient characteristics 2, 1:
Standard dose: 5 mg twice daily for most patients
Reduced dose: 2.5 mg twice daily ONLY if the patient meets at least 2 of these 3 criteria:
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL
This is critical because inappropriate dose reduction is extremely common in clinical practice—one study found 61% of patients receiving reduced-dose apixaban did not actually meet criteria for dose reduction 3. Underdosing exposes patients to preventable strokes.
Key Clinical Pitfalls to Avoid
Do not reduce the dose based on a single criterion alone. The 2024 ACC/AHA/ACCP/HRS guidelines and FDA labeling are explicit that two or more dose-reduction criteria must be present 2, 1. Physicians commonly make the error of reducing the dose based solely on advanced age or mild renal impairment when the patient doesn't meet the full criteria.
Do not use a loading dose regimen. The 10 mg twice daily loading dose for 7 days is reserved exclusively for acute DVT/PE treatment, not for atrial fibrillation 1. Starting with standard maintenance dosing (5 mg or 2.5 mg twice daily based on criteria above) provides adequate anticoagulation for stroke prevention in AF.
Timing Considerations
Since clopidogrel has a half-life of approximately 6 hours for its active metabolite and its antiplatelet effects last for the lifespan of platelets (7-10 days), there is no concern about a "gap" in antithrombotic coverage when making this switch. The patient's stroke risk from atrial fibrillation is addressed immediately once Eliquis is started at the next scheduled dose time.
The 2024 ESC guidelines confirm that DOACs like apixaban are preferred over vitamin K antagonists for stroke prevention in AF, with demonstrated reductions in intracranial hemorrhage 4. This makes the switch from Plavix (which provides no stroke protection in AF) to Eliquis both appropriate and urgent.